Abstract: The disclosure relates to a genetically engineered Z. mobilis ZM4 for producing PHB and uses thereof. A variety of strains capable of producing both PHB and ethanol that are constructed by integrating three codon-optimized essential genes for exogenous PUB biosynthesis, phaA, phaB and phaC, together with a tetracycline-inducible promoter Ptet into the genome of ZM4.

Abstract: An application of polyethylene glycol (PEG)-interferon and a protooncogene product targeting inhibitor in synergistic inhibition of tumors. Specifically, provided is use of an active ingredient combination. The active ingredient combination comprises PEG-interferon and a protooncogene product targeting inhibitor, and the combination is used for preparing a pharmaceutical composition for synergistic treatment of tumors. The active ingredient combination can synergistically inhibit the growth of tumors (especially lung, stomach, breast and liver cancers) effectively, and can significantly reduce toxic and side effects, and therefore can be widely used in targeted therapy of the tumors.

Abstract: A composition that includes tahina and probiotic bacteriais can be formulated for oral administration. The composition can also include at least one polyphenol originating in a plant other than sesame. The composition can be used in treatment of a neurodegenerative disease or disorder, such as Alzheimer's disease. A method for the preparation of the composition includes intimately mixing the tahina and the probiotic bacteria, while homogenizing without damaging the probiotic bacteria. The composition can be encapsulated within a pH-dependent enteric-coating polymer capable of protecting the mixture from gastric (stomach) acidity.

Abstract: A QA test slide for use in a stain QA method for a stain and method of making QA test slides are described. The QA test slide comprises: a transparent substrate; a piece of biopolymer material mounted on the transparent substrate; and a sticker defining an aperture and adhered to the transparent substrate over the piece of biopolymer material and with a portion of the piece of biopolymer material exposed by the aperture and wherein a machine readable code is borne by the sticker and the machine readable code encodes a unique identifier for the QA test slide.

Abstract: The present disclosure provides a gene combination for expressing and producing terrequinone A in Escherichia coli and use thereof. The gene combination includes a tdiAS gene, a tdiBS gene, a tdiCS gene, a tdiDS gene, a tdiES gene, an sfpS gene, an ScCKS gene, and an AtIPKS gene with nucleotide sequences set forth in SEQ ID NOS:1 to 8. In the present disclosure, a recombinant engineered strain capable of producing terrequinone A having anti-cancer activity is obtained by separately constructing recombinant plasmids pC02 and pU03 through the eight genes and transforming the two recombinant plasmids into E. coli. The content of terrequinone A in a fermentation broth thereof is 106.3 mg/L, which has potential application value in the biopharmaceutical field.

Abstract: A technique capable of achieving production of a biological material using photosynthetic microorganisms at low cost is provided. A method of producing a biological material includes culturing photosynthetic microorganisms in a culture medium containing dimethyl 2-oxoglutarate while the photosynthetic microorganisms are irradiated with light to cause the photosynthetic microorganisms to proliferate, and then collecting a substance produced by or accumulated in the photosynthetic microorganisms.

Abstract: The present invention provides a clostridial neurotoxin for use in a method of treating a brain disorder in a patient by promoting a neuroimmune response.

Abstract: The present application provides a protein heterodimer and use thereof. The protein heterodimer comprises a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain comprises IL12a, and the second polypeptide chain comprises interleukin-12b (IL12b). The protein heterodimer also comprises interleukin-2 (IL2) or its functional fragments, granulocyte macrophage colony stimulating factor (GMCSF) or its functional fragments, and one or more targeting moieties. The protein heterodimer can be used for the treatment of tumors.

Abstract: Provided are compositions and methods related to improved mucins, methods of making the improved mucins, and cells and cell cultures that express glycosylated mucins. The compositions and methods provide improved cell cultures, and improved methods of producing co-expressed proteins that are distinct from the mucins.

Abstract: The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.

Abstract: The present invention relates to a composition comprising a Leuconostoc citreum strain or its culture as an active ingredient for preventing, improving or treating cholestatic liver injury, specifically primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various cholestatic liver injuries, the composition can be usefully used as a composition for the treatment, prevention, improvement, or the like of cholestatic liver injury in humans or animals.

Abstract: Described herein are antigen-binding molecules that bind to bacteria (e.g., Listeria monocytogenes) and methods of use thereof. Also described herein are compositions and kits comprising these antigen-binding molecules.

Abstract: The present invention relates to animals and more specifically to insects. In more details the invention relates to an edible composition or insect artificial diet comprising bacteria, fungi or any fragment or spore thereof for use as a vaccine in preventing a microbial disease or infection in an insect. Still, the present invention relates to preventive methods and different uses relating to said compositions or bacteria, fungi or fragments or spores thereof.

Abstract: An isolated antibody or fragment thereof, which specifically binds to a gamma variable 4 (V?4) chain of a ?? T cell receptor (TCR) and not to a gamma variable 2 (V?2) chain of a ?? TCR is provided herein. Methods of treatment and other uses of said antibodies are also provided along with methods of producing said antibodies.

Abstract: The present invention generally relates to the field of skin care. More particularly, the invention relates to a cosmetic or therapeutic skin care composition comprising live bacteria of at least one Cutibacterium acnes (C. acnes) strain in combination with an excipient that specifically supports their viability during storage and/or their ability to replicate after application to the skin. Preferably, the cosmetic or therapeutic skin care composition comprises bacteria of at least one C. acnes strain selected from the group consisting of D1, A5, C1, C3, H1, H2, H3, K1, K2, K4, K6, K8, K9, L1, and F4. The invention also provides a method for treating or preventing acne by applying the skin care composition of the invention to a skin area in need of treatment. The invention also relates to the use of a skin care composition of the invention for treating or preventing acne.

Abstract: The present disclosure provides a chitosan-Fe coating-based synbiotic microcapsule with gastric acid resistance and intestinal targeted release and a preparation method thereof. The preparation method includes the following steps: preparation of mixed probiotics, preparation of a chitosan-Fe coating, preparation of a microcapsule, and freeze-drying. In the present disclosure, live probiotics wrapped in the microcapsule can avoid a weak acid resistance and a poor long-term storage stability of the probiotics; chitosan-Fe added to a wall material can significantly improve an embedding rate of the microcapsule, and can also achieve targeted release of the probiotics in the intestinal tract.

Abstract: The present invention provides compositions and methods comprising an activator of interleukin-18 (IL-18) activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule 5 such as IL-18 binding protein (IL-18BP).

Abstract: The present disclosure provides, in part, a method of treating an autoimmune disease in a subject by reducing the number of pDCs through administration of a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3). The disclosure also generally relates to methods of monitoring the effectiveness of therapy in subjects receiving DT-IL3 for treating an autoimmune disease, and methods of determining continuing treatment of subjects receiving DT-IL3 for treating an autoimmune disease. The disclosure also provides pharmaceutical compositions of DT-IL3 for use in such methods.

Abstract: This invention provides an immunomodulator for use in the treatment, reduction, inhibition or control of cancer subject, wherein the subject is clinically classified as having a performance status of 1-, 2, 3 or 4 according to the ECOG Scale, or classified as not being of an age and/or not being sufficiently fit to tolerate two or more chemotherapy regimens. The invention also describes the use of one or more additional anticancer treatments or agents as well as protocols and dosage regimens for use.

Abstract: A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-? (TNF-?), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-? (MIP-1?) or interleukin-6 (IL-6).